Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. again there was an imbalance in the number of treatment cycles Docetaxel as Neoadjuvant Therapy in Early- [5] [6] between the two treatment arms. In the Aberdeen trial, Stage or Locally Advanced Breast Cancer docetaxel sequential to cyclophosphamide, vincristine, doxoru- A Viewpoint by T.R. Jeffry Evans bicin plus prednisone resulted in a significantly greater pCR rate than that achieved by further administration of anthracycline- Centre for Oncology and Applied Pharmacology, Cancer based treatment. Of further interest was the clinical response to Research UK Beatson Laboratories, University of Glasgow, Glasgow, Scotland docetaxel that was seen in patients in this study who were resistant to anthracycline therapy. Concurrent administration of doxoru- bicin and docetaxel (AD) compared to AC demonstrated a trend to Primary (neoadjuvant) chemotherapy is increasingly used in a superior clinical response rate with AD compared with AC as the management of patients with locally advanced or large primary [7] primary chemotherapy in breast cancer. There was no evidence (>3cm) breast cancers. The aims of such an approach are to reduce of a difference in the pCR rate or the rates http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

American Journal of Cancer , Volume 5 (3) – Aug 10, 2012

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer

Abstract

Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. again there was an imbalance in the number of treatment cycles Docetaxel as Neoadjuvant Therapy in Early- [5] [6] between the two treatment arms. In the Aberdeen trial, Stage or Locally Advanced Breast Cancer docetaxel sequential to cyclophosphamide, vincristine, doxoru- A Viewpoint by T.R. Jeffry Evans bicin plus prednisone resulted in a significantly...
Loading next page...
 
/lp/springer-journals/docetaxel-as-neoadjuvant-therapy-in-early-stage-or-locally-advanced-NqY415b9Fe
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605030-00009
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (3): 207-209 GUEST COMMENTARIES 1175-6357/06/0003-0207/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. again there was an imbalance in the number of treatment cycles Docetaxel as Neoadjuvant Therapy in Early- [5] [6] between the two treatment arms. In the Aberdeen trial, Stage or Locally Advanced Breast Cancer docetaxel sequential to cyclophosphamide, vincristine, doxoru- A Viewpoint by T.R. Jeffry Evans bicin plus prednisone resulted in a significantly greater pCR rate than that achieved by further administration of anthracycline- Centre for Oncology and Applied Pharmacology, Cancer based treatment. Of further interest was the clinical response to Research UK Beatson Laboratories, University of Glasgow, Glasgow, Scotland docetaxel that was seen in patients in this study who were resistant to anthracycline therapy. Concurrent administration of doxoru- bicin and docetaxel (AD) compared to AC demonstrated a trend to Primary (neoadjuvant) chemotherapy is increasingly used in a superior clinical response rate with AD compared with AC as the management of patients with locally advanced or large primary [7] primary chemotherapy in breast cancer. There was no evidence (>3cm) breast cancers. The aims of such an approach are to reduce of a difference in the pCR rate or the rates

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References